Thanks to our label-free approach it is possible to study the interaction of your therapeutic candidate directly on crude human tissue at an early phase of drug development.
Inoviem Scientific has developed cutting-edge technologies for drug-target interaction analysis with the aim of taking account of the whole natural and physiological environment with which the molecule will come into contact.
Combining high-technology, physiology, and speed is the biggest challenge the pharmaceutical industry has had to face over the past decade.
It is a challenge which has yet to be met by current conventional technologies, resulting in the introduction of bias in the development of drug candidates. Inoviem has overcome the difficulties associated with this challenge and offers any company involved in the development of therapeutic molecules (proteins, peptides, small chemical molecules, fragments and antibodies) the opportunity to integrate quick high-value information into their drug development program.
Our primary goal is to help our clients deliver tomorrow’s medicines faster and more safely by adding the physiological dimension made possible thanks to our technologies.